Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793726 | 0.90 | RAB9A (0.52) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL3368530 | 0.84 | LMNA (0.56) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL3365491 | 0.82 | RAB9A (0.52) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL3365185 | 0.81 | LMNA (0.54) | LMNARAB9ANPC1MAPK1SMN1; SMN2 | |
| SCHEMBL2896507 | 0.81 | RAB9A (0.44) | LMNARAB9ANPC1MAPK1SMN1; SMN2 | |
| SCHEMBL3368170 | 0.80 | RAB9A (0.60) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL3368622 | 0.80 | LMNA (0.57) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL3368618 | 0.80 | LMNA (0.57) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL13703961 | 0.79 | LMNA (0.48) | LMNARAB9ANPC1KMT2AKCNH2 | |
| SCHEMBL1544567 | 0.77 | NPC1 (0.44) | LMNARAB9ANPC1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | LMNA 4509/4885RAB9A 1926/4885NPC1 554/4885 |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | LMNA 4539/4885RAB9A 1785/4885NPC1 609/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | LMNA 4509/4885RAB9A 1926/4885NPC1 554/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | LMNA 4509/4885RAB9A 1926/4885NPC1 554/4885 |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | LMNA 4509/4885RAB9A 1926/4885NPC1 554/4885 |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | LMNA 4509/4885RAB9A 1926/4885NPC1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.